GlassScriptPhysician profile
Samuel A Gurevich
NPI 1134109044
$1,172.01
in general payments reported to CMS, 2019-2025
18 companies · $558 in 2025
The $558 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $49.28 · 2021: $50.15 · 2022: $35.28 · 2023: $24.99 · 2024: $141 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.41 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $200.00 | 2025 | Lumryz |
| Glaxosmithkline, LLC. | $158.80 | 2019-2024 | |
| Alcon Vision LLC | $154.77 | 2019 | |
| Jazz Pharmaceuticals INC. | $150.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $117.90 | 2025 | Fasenra |
| Grifols USA, LLC | $64.76 | 2019 | |
| Intuitive Surgical, INC. | $64.50 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.36 | 2023-2024 | Ofev |
| Inspire Medical Systems, INC. | $31.32 | 2025 | Inspire |
| Lungpacer Medical USA INC | $30.91 | 2025 | Aeropace Neurostimulation Console |
| Eisai INC. | $28.35 | 2025 | |
| Getinge USA Sales, LLC | $26.14 | 2019 | |
| Genentech USA, INC. | $19.57 | 2019 | |
| Covidien LP | $17.08 | 2020 | |
| Merck Sharp & Dohme LLC | $16.73 | 2024 | Keytruda |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14.41 | 2019 | |
| Novo Nordisk INC | $13.68 | 2020 | |
| Boston Scientific Corporation | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Gurevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.